TY - JOUR
T1 - Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy
AU - Yin, Vivian T.
AU - Wiraszka, Tomasz A.
AU - Tetzlaff, Michael
AU - Curry, Jonathan L.
AU - Esmaeli, Bita
N1 - Publisher Copyright:
Copyright © 2015 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.
PY - 2015/7/20
Y1 - 2015/7/20
N2 - The discovery of BRAF mutation in ∼50% of melanomas led to the development of small molecule BRAF inhibitors, including sorafenib, debrafenib, and vemurafenib. Clinical trials have shown these agents to be effective in treatment of metastatic and locally advanced melanoma, increasing overall and progression-free survival. However, some of the most common toxicities associated with BRAF inhibitor therapy include adverse skin events such as rashes, photosensitivity, hyperkeratosis, papillomas, keratoacanthomas, and squamous cell carcinomas. Here, the authors describe 3 patients who developed keratinocytic neoplasms on the eyelid, including invasive squamous carcinoma secondary to vemurafenib. Vigilant screening and a high index of suspicion for eyelid carcinomas are recommended in patients treated with vemurafenib.
AB - The discovery of BRAF mutation in ∼50% of melanomas led to the development of small molecule BRAF inhibitors, including sorafenib, debrafenib, and vemurafenib. Clinical trials have shown these agents to be effective in treatment of metastatic and locally advanced melanoma, increasing overall and progression-free survival. However, some of the most common toxicities associated with BRAF inhibitor therapy include adverse skin events such as rashes, photosensitivity, hyperkeratosis, papillomas, keratoacanthomas, and squamous cell carcinomas. Here, the authors describe 3 patients who developed keratinocytic neoplasms on the eyelid, including invasive squamous carcinoma secondary to vemurafenib. Vigilant screening and a high index of suspicion for eyelid carcinomas are recommended in patients treated with vemurafenib.
UR - http://www.scopus.com/inward/record.url?scp=84937643784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937643784&partnerID=8YFLogxK
U2 - 10.1097/IOP.0000000000000140
DO - 10.1097/IOP.0000000000000140
M3 - Article
C2 - 24833447
AN - SCOPUS:84937643784
SN - 0740-9303
VL - 31
SP - e112-e115
JO - Ophthalmic plastic and reconstructive surgery
JF - Ophthalmic plastic and reconstructive surgery
IS - 4
ER -